The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Cannabinoid type-2 receptors: An emerging target for regulating schizophrenia-relevant brain circuits
Abstract
Although the cannabinoid type-2 receptor (CB2) is highly expressed in the immune system, emerging evidence points to CB2 playing a key role in regulating neuronal function in the central nervous system. Recent anatomical studies, combined with electrophysiological studies, indicate that CB2 receptors are expressed in specific dopaminergic and glutamatergic brain circuits that are hyperactive in schizophrenia patients. The ability of CB2 receptors to inhibit dopaminergic and hippocampal circuits, combined with the anti-inflammatory effects of CB2 receptor activation, make this receptor an intriguing target for treating schizophrenia, a disease where novel interventions that move beyond dopamine receptor antagonists are desperately needed. The development of new CB2-related pharmacological and genetic tools, including the first small molecule positive allosteric modulator of CB2 receptors, has greatly advanced our understanding of this receptor. While more work is needed to further elucidate the translational value of selectively targeting CB2 receptors with respect to schizophrenia, the studies discussed below could suggest that CB2 receptors are anatomically located in schizophrenia-relevant circuits, where the physiological consequence of CB2 receptor activation could correct circuit-based deficits commonly associated with positive and cognitive deficits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While CB1 is mostly expressed by neurons, CB2 is primarily expressed by immune cells.”
From Novel floxed cannabinoid receptor 2 mouse line combines knockout capability with dual fluorescent reporters (2025) · cites this paper as Ferranti and Foster, 2022
In the citing paper
“CB2 expression is upregulated during inflammation and is understood to play a crucial role in immune modulation”
From Novel floxed cannabinoid receptor 2 mouse line combines knockout capability with dual fluorescent reporters (2025) · cites this paper as Ferranti and Foster, 2022
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification and Functional Characterization of Brainstem Cannabinoid CB2Receptors
Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J. S., et al. (2005) · Science · doi:10.1126/science.1115740 · Cited by 1,470
The endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2760 · Cited by 1,063
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059 · cited 1×
“The phytocannabinoid CBD has been reported to potentially play a role in mitigating the ability of delta-9-THC to induce psychosis (Morgan and Curran, 2008), as well as alleviate psychosis in schizophrenia patients (Leweke et al., 2012; McGuire et al., 2018).”
BackgroundMoghaddam, B., & Javitt, D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.181 · Cited by 1,035
Beta-caryophyllene is a dietary cannabinoid.
Gertsch, J., Leonti, M., Raduner, S., Racz, I., Chen, J.-Z., Xie, X.-Q., Altmann, K.-H., Karsak, M., & Zimmer, A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803601105 · Cited by 906
Effects of Cannabis Use on Human Behavior, Including Cognition, Motivation, and Psychosis: A Review
Volkow, N. D., Swanson, J. M., Evins, A. E., DeLisi, L. E., Meier, M. H., Gonzalez, R., Bloomfield, M. A. P., Curran, H. V., & Baler, R. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.3278 · Cited by 867
Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations.
Müller, N. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sby024 · Cited by 648 · cited 1×
“This includes changes in numerous cytokine levels in the blood and cerebrospinal fluid of schizophrenia patients, as well as in the increased comorbidity of schizophrenia with auto-immune disorders (Muller, 2018).”
BackgroundBrain cannabinoid CB2 receptors modulate cocaine's actions in mice
Xi, Z.-X., Peng, X.-Q., Li, X., Song, R., Zhang, H.-Y., Liu, Q.-R., Yang, H.-J., Bi, G.-H., Li, J., & Gardner, E. L. (2011) · Nature Neuroscience · doi:10.1038/nn.2874 · Cited by 397
Zhang, H.-Y., Gao, M., Liu, Q.-R., Bi, G.-H., Li, X., Yang, H.-J., Gardner, E. L., Wu, J., & Xi, Z.-X. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1413210111 · Cited by 334
Research works printed but not linked: 116
- Aracil-Fernández, 2012, Decreased cocaine motor sensitization and self-administration in mice overexpressing cannabinoid CB2 receptors., Neuropsychopharmacology, 37, 1749, 10.1038/npp.2012.22 · DOI
- Ashton, 2006, Expression of the cannabinoid CB2 receptor in the rat cerebellum: An immunohistochemical study., Neurosci. Lett., 396, 113, 10.1016/j.neulet.2005.11.038 · DOI · Paper page
- Atwood, 2010, CB2: A cannabinoid receptor with an identity crisis., Br. J. Pharmacol., 160, 467, 10.1111/j.1476-5381.2010.00729.x · DOI · Paper page
- Beltramo, 2009, Cannabinoid type 2 receptor as a target for chronic - pain., Mini Rev. Med. Chem., 9, 11, 10.2174/138955709787001785 · DOI
- Bian, 2022, Artificial Intelligent deep learning molecular generative modeling of scaffold-focused and cannabinoid CB2 target-specific small-molecule sublibraries., Cells, 11, 10.3390/cells11050915 · DOI
- Boggs, 2018, The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial., Psychopharmacology, 235, 1923, 10.1007/s00213-018-4885-9 · DOI · Paper page
- Bouchard, 2012, Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington’s disease., J. Neurosci., 32, 18259, 10.1523/JNEUROSCI.4008-12.2012 · DOI
- Brown, 2002, Cloning and molecular characterization of the rat CB2 cannabinoid receptor., Biochim. Biophys. Acta, 1576, 255, 10.1016/S0167-4781(02)00341-X · DOI · Paper page
- Brusco, Ultrastructural localization of neuronal brain CB2 cannabinoid receptors., Ann. N.Y.Acad. Sci., 1139, 450, 10.1196/annals.1432.037 · DOI · Paper page
- Brusco, Postsynaptic localization of CB2 cannabinoid receptors in the rat hippocampus., Synapse, 62, 944, 10.1002/syn.20569 · DOI · Paper page
- Buckley, 2008, The peripheral cannabinoid receptor knockout mice: An update., Br. J. Pharmacol., 153, 309, 10.1038/sj.bjp.0707527 · DOI
- Busquets-Garcia, 2017, Pregnenolone blocks cannabinoid-induced acute psychotic-like states in mice., Mol. Psychiatry, 22, 1594, 10.1038/mp.2017.4 · DOI
- Byun, 2014, Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100., Neuropsychopharmacology, 39, 1578, 10.1038/npp.2014.2 · DOI
- Cabanero, 2020, Protective role of neuronal and lymphoid cannabinoid CB2 receptors in neuropathic pain., Elife, 9, 255, 10.7554/eLife.55582 · DOI
- Canseco-Alba, 2021, Cell-type specific deletion of CB2 cannabinoid receptors in dopamine neurons induced hyperactivity phenotype: Possible relevance to attention-deficit hyperactivity disorder., Front. Psychiatry, 12, 10.3389/fpsyt.2021.803394 · DOI
- Canseco-Alba, 2019, Behavioral effects of psychostimulants in mutant mice with cell-type specific deletion of CB2 cannabinoid receptors in dopamine neurons., Behav. Brain Res., 360, 286, 10.1016/j.bbr.2018.11.043 · DOI
- de Oliveira, 2022, CB2 and toll-like receptors crosstalk in microglia., Trends Neurosci., 45, 1, 10.1016/j.tins.2021.10.012 · DOI
- Delis, 2017, Attenuation of cocaine-induced conditioned place preference and motor activity via cannabinoid CB2 receptor agonism and CB1 receptor antagonism in rats., Int. J. Neuropsychopharmacol., 20, 269, 10.1093/ijnp/pyw102 · DOI
- den Boon, 2014, Endocannabinoids produced upon action potential firing evoke a Cl- current via type-2 cannabinoid receptors in the medial prefrontal cortex., Pflügers Archiv., 466, 2257, 10.1007/s00424-014-1502-6 · DOI
- den Boon, 2012, Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors., Proc. Natl. Acad. Sci. U.S.A., 109, 3534, 10.1073/pnas.1118167109 · DOI · Paper page
- Dhopeshwarkar, 2016, Functional selectivity of CB2 cannabinoid receptor ligands at a canonical and noncanonical pathway., J. Pharmacol. Exp. Ther., 358, 342, 10.1124/jpet.116.232561 · DOI
- Di Forti, 2014, Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users., Schizophr. Bull., 40, 1509, 10.1093/schbul/sbt181 · DOI · Paper page
- Di Marzo, 2018, New approaches and challenges to targeting the endocannabinoid system., Nat. Rev. Drug Discov., 17, 623, 10.1038/nrd.2018.115 · DOI · Paper page
- Dogra, 2021, Activating mGlu3 metabotropic glutamate receptors rescues schizophrenia-like cognitive deficits through metaplastic adaptations within the hippocampus., Biol. Psychiatry, 90, 385, 10.1016/j.biopsych.2021.02.970 · DOI
- Dong, 2021, A fluorescent sensor for spatiotemporally resolved imaging of endocannabinoid dynamics in vivo., Nat. Biotechnol., 40, 787, 10.1038/s41587-021-01074-4 · DOI · Paper page
- D’Souza, 2004, The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis., Neuropsychopharmacology, 29, 1558, 10.1038/sj.npp.1300496 · DOI · Paper page
- Duffy, 2021, The cannabinoid system and microglia in health and disease., Neuropharmacology, 190, 10.1016/j.neuropharm.2021.108555 · DOI · Paper page
- Foster, 2017, Allosteric modulation of GPCRs: New insights and potential utility for treatment of schizophrenia and other CNS disorders., Neuron, 94, 431, 10.1016/j.neuron.2017.03.016 · DOI · Paper page
- Foster, 2016, Antipsychotic-like effects of M4 positive allosteric modulators are mediated by CB2 receptor-dependent inhibition of dopamine release., Neuron, 91, 1244, 10.1016/j.neuron.2016.08.017 · DOI
- Gado, 2019, Identification of the first synthetic allosteric modulator of the CB2 receptors and evidence of its efficacy for neuropathic pain relief., J. Med. Chem., 62, 276, 10.1021/acs.jmedchem.8b00368 · DOI
- Gado, 2022, Design, synthesis, and biological activity of new CB2 receptor ligands: From orthosteric and allosteric modulators to dualsteric/bitopic ligands., J. Med. Chem., 65, 9918, 10.1021/acs.jmedchem.2c00582 · DOI
- Galaj, 2020, Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5-HT(1A) and TRPV1 receptor mechanisms., Neuropharmacology, 167, 10.1016/j.neuropharm.2019.107740 · DOI
- Galiègue, 1995, Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations., Eur. J. Biochem., 232, 54, 10.1111/j.1432-1033.1995.tb20780.x · DOI · Paper page
- Gantz, 2017, Cell-autonomous excitation of midbrain dopamine neurons by endocannabinoid-dependent lipid signaling., Neuron, 93, 1375.e, 10.1016/j.neuron.2017.02.025 · DOI
- García-Gutiérrez, 2018, Alterations in gene and protein expression of cannabinoid CB2 and GPR55 receptors in the dorsolateral prefrontal cortex of suicide victims., Neurotherapeutics, 15, 796, 10.1007/s13311-018-0610-y · DOI
- García-Gutiérrez, 2013, Synaptic plasticity alterations associated with memory impairment induced by deletion of CB2 cannabinoid receptors., Neuropharmacology, 73, 388, 10.1016/j.neuropharm.2013.05.034 · DOI
- Giuffrida, 2004, Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms., Neuropsychopharmacology, 29, 2108, 10.1038/sj.npp.1300558 · DOI · Paper page
- Gong, 2006, Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain., Brain Res., 1071, 10, 10.1016/j.brainres.2005.11.035 · DOI · Paper page
- Hallak, 2010, Performance of schizophrenic patients in the stroop color word test and electrodermal responsiveness after acute administration of cannabidiol (CBD)., Braz. J. Psychiatry, 32, 56, 10.1590/s1516-44462010000100011 · DOI
- Han, 2014, Latest progress in the identification of novel synthetic ligands for the cannabinoid CB2 receptor., Mini Rev. Med. Chem., 14, 426, 10.2174/1389557514666140428105753 · DOI
- Hanus, 1999, HU-308: A specific agonist for CB2, a peripheral cannabinoid receptor., Proc. Natl. Acad. Sci. U.S.A., 96, 14228, 10.1073/pnas.96.25.14228 · DOI · Paper page
- Howes, 2009, The dopamine hypothesis of schizophrenia: Version III–the final common pathway., Schizophr. Bull., 35, 549, 10.1093/schbul/sbp006 · DOI · Paper page
- Howlett, 2002, International union of pharmacology. XXVII. classification of cannabinoid receptors., Pharmacol. Rev., 54, 161, 10.1124/pr.54.2.161 · DOI · Paper page
- Hua, 2020, Activation and signaling mechanism revealed by cannabinoid receptor-Gi complex structures., Cell, 180, 655, 10.1016/j.cell.2020.01.008 · DOI · Paper page
- Incontro, 2021, Endocannabinoids tune intrinsic excitability in O-LM interneurons by direct modulation of postsynaptic Kv7 channels., J. Neurosci., 41, 9521, 10.1523/jneurosci.1279-21.2021 · DOI
- Ishiguro, 2010, Brain cannabinoid CB2 receptor in schizophrenia., Biol. Psychiatry, 67, 974, 10.1016/j.biopsych.2009.09.024 · DOI · Paper page
- Ji, 2021, The CB2 receptor as a novel therapeutic target for epilepsy treatment., Int. J. Mol. Sci., 22, 10.3390/ijms22168961 · DOI
- Jordan, 2020, Xie2-64, a novel CB2 receptor inverse agonist, reduces cocaine abuse-related behaviors in rodents., Neuropharmacology, 176, 108241, 10.1016/j.neuropharm.2020.108241 · DOI
- Kano, 2009, Endocannabinoid-mediated control of synaptic transmission., Physiol. Rev., 89, 309, 10.1152/physrev.00019.2008 · DOI · Paper page
- Khella, 2014, CB2 receptor agonism reverses MK-801-induced disruptions of prepulse inhibition in mice., Psychopharmacology, 231, 3071, 10.1007/s00213-014-3481-x · DOI
- Kim, 2015, Chronic activation of CB2 cannabinoid receptors in the hippocampus increases excitatory synaptic transmission., J. Physiol., 593, 871, 10.1113/jphysiol.2014.286633 · DOI
- Kohler-Forsberg, 2020, Editorial: The role of inflammation in the etiology and treatment of schizophrenia., Front. Psychiatry, 11, 10.3389/fpsyt.2020.603296 · DOI
- Komorowska-Müller, 2020, CB2 receptor in microglia: The guardian of self-control., Int. J. Mol. Sci., 22, 10.3390/ijms22010019 · DOI · Paper page
- Komorowska-Müller, Cannabinoid receptor 2 alters social memory and microglial activity in an age-dependent manner., Molecules, 26, 10.3390/molecules26195984 · DOI
- Komorowska-Müller, Cannabinoid receptor 2 deletion influences social memory and synaptic architecture in the hippocampus., Sci. Rep., 11, 16828, 10.1038/s41598-021-96285-9 · DOI
- Lan, 1999, Design and synthesis of the CB1 selective cannabinoid antagonist AM281: A potential human SPECT ligand., AAPS PharmSci, 1, 10.1208/ps010204 · DOI
- Lanciego, 2011, Expression of the mRNA coding the cannabinoid receptor 2 in the pallidal complex of Macaca fascicularis., J. Psychopharmacol., 25, 97, 10.1177/0269881110367732 · DOI
- Legge, 2019, Association of genetic liability to psychotic experiences with neuropsychotic disorders and traits., JAMA Psychiatry, 76, 1256, 10.1001/jamapsychiatry.2019.2508 · DOI
- Li, 2021, Cannabinoid receptor 2 deficiency enhances isoflurane-induced spatial cognitive impairment in adult mice by affecting neuroinflammation, neurogenesis and neuroplasticity., Exp. Ther. Med., 22, 908, 10.3892/etm.2021.10340 · DOI
- Li, 2015, Neuronal expression of CB2 cannabinoid receptor mRNAs in the mouse hippocampus., Neuroscience, 311, 253, 10.1016/j.neuroscience.2015.10.041 · DOI
- Li, CB2 cannabinoid receptor knockout in mice impairs contextual long-term memory and enhances spatial working memory., Neural Plast., 2016, 10.1155/2016/9817089 · DOI
- Li, Deletion of CB2 cannabinoid receptors reduces synaptic transmission and long-term potentiation in the mouse hippocampus., Hippocampus, 26, 275, 10.1002/hipo.22558 · DOI
- Li, 2017, Distinct roles of neuronal and microglial CB2 cannabinoid receptors in the mouse hippocampus., Neuroscience, 363, 11, 10.1016/j.neuroscience.2017.08.053 · DOI
- Lieberman, 2018, Hippocampal dysfunction in the pathophysiology of schizophrenia: A selective review and hypothesis for early detection and intervention., Mol. Psychiatry, 23, 1764, 10.1038/mp.2017.249 · DOI · Paper page
- Lin, 2021, A peripheral CB2 cannabinoid receptor mechanism suppresses chemotherapy-induced peripheral neuropathy: Evidence from a CB2: Reporter mouse., PAIN, 163, 834, 10.1097/j.pain.0000000000002502 · DOI
- Liu, 2017, Cannabinoid type 2 receptors in dopamine neurons inhibits psychomotor behaviors, alters anxiety, depression and alcohol preference., Sci. Rep., 7, 10.1038/s41598-017-17796-y · DOI · Paper page
- Lopes, 2020, The roles of cannabinoid CB1 and CB2 receptors in cocaine-induced behavioral sensitization and conditioned place preference in mice., Psychopharmacology, 237, 385, 10.1007/s00213-019-05370-5 · DOI
- López-Ramírez, 2020, D2autoreceptor switches CB2receptor effects on [3H]-dopamine release in the striatum., Synapse, 74, 10.1002/syn.22139 · DOI
- Lu, 2021, Review of the endocannabinoid system., Biol. Psychiatry Cogn. Neurosci. Neuroimaging, 6, 607, 10.1016/j.bpsc.2020.07.016 · DOI · Paper page
- Manzanares, 2018, Role of the endocannabinoid system in drug addiction., Biochem. Pharmacol., 157, 108, 10.1016/j.bcp.2018.09.013 · DOI
- McCoy, 1999, Cannabinoid inhibition of the processing of intact lysozyme by macrophages: Evidence for CB2 receptor participation., J. Pharmacol. Exp. Ther., 289, 1620
- McGuire, 2018, Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter randomized controlled Trial., Am. J. Psychiatry, 175, 225, 10.1176/appi.ajp.2017.17030325 · DOI · Paper page
- Minichino, 2019, Measuring disturbance of the endocannabinoid system in psychosis: A systematic review and meta-analysis., JAMA Psychiatry, 76, 914, 10.1001/jamapsychiatry.2019.0970 · DOI
- Miranzadeh Mahabadi, 2021, Cannabinoid receptors distribution in mouse cortical plasma membrane compartments., Mol. Brain, 14, 10.1186/s13041-021-00801-x · DOI
- Monory, 2007, Genetic dissection of behavioural and autonomic effects of Delta(9)-tetrahydrocannabinol in mice., PLoS Biol., 5, 10.1371/journal.pbio.0050269 · DOI · Paper page
- Morales, 2016, Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update., Expert. Opin. Ther. Pat., 26, 843, 10.1080/13543776.2016.1193157 · DOI
- Morgan, 2008, Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis., Br. J. Psychiatry, 192, 306, 10.1192/bjp.bp.107.046649 · DOI · Paper page
- Munro, 1993, Molecular characterization of a peripheral receptor for cannabinoids., Nature, 365, 61, 10.1038/365061a0 · DOI · Paper page
- Murineddu, 2013, Different classes of CB2 ligands potentially useful in the treatment of pain., Recent Pat. CNS Drug Discov., 8, 42, 10.2174/15748898112079990016 · DOI
- Navarrete, 2021, CB2 receptor involvement in the treatment of substance use disorders., Biomolecules, 11, 10.3390/biom11111556 · DOI
- Navarro, 2021, Design of negative and positive allosteric modulators of the cannabinoid CB2 receptor derived from the natural product cannabidiol., J. Med. Chem., 64, 9354, 10.1021/acs.jmedchem.1c00561 · DOI
- Onaivi, 2006, Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain., Neuropsychobiology, 54, 231, 10.1159/000100778 · DOI · Paper page
- Onaivi, 2006, Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain., Ann. N.Y . Acad. Sci., 1074, 514, 10.1196/annals.1369.052 · DOI · Paper page
- Ortega-Alvaro, 2011, Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice., Neuropsychopharmacology, 36, 1489, 10.1038/npp.2011.34 · DOI · Paper page
- Pacher, 2006, The endocannabinoid system as an emerging target of pharmacotherapy., Pharmacol. Rev., 58, 389, 10.1124/pr.58.3.2 · DOI · Paper page
- Pertwee, 2008, Ligands that target cannabinoid receptors in the brain: From THC to anandamide and beyond., Addict. Biol., 13, 147, 10.1111/j.1369-1600.2008.00108.x · DOI · Paper page
- Pertwee, 2010, International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB(1) and CB(2)., Pharmacol. Rev., 62, 588, 10.1124/pr.110.003004 · DOI · Paper page
- Petrucci, 2017, Pepcan-12 (RVD-hemopressin) is a CB2 receptor positive allosteric modulator constitutively secreted by adrenals and in liver upon tissue damage., Sci. Rep., 7, 10.1038/s41598-017-09808-8 · DOI
- Polini, 2020, Positive allosteric modulation of CB1 and CB2 cannabinoid receptors enhances the neuroprotective activity of a dual CB1R/CB2R orthosteric agonist., Life, 10, 10.3390/life10120333 · DOI
- Reusch, 2022, Cannabinoid receptor 2 is necessary to induce toll-like receptor-mediated microglial activation., Glia, 70, 71, 10.1002/glia.24089 · DOI
- Rinaldi-Carmona, 1998, SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor., J. Pharmacol. Exp. Ther., 284, 644
- Rivas-Santisteban, 2021, N-Methyl-D-aspartate (n.d.) and cannabinoid CB(2) receptors form functional complexes in cells of the central nervous system: Insights into the therapeutic potential of neuronal and microglial NMDA receptors., Alzheimer’s Res. Ther., 13, 184, 10.1186/s13195-021-00920-6 · DOI
- Rodrigues da Silva, 2020, Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors., Pharmacol. Res., 156, 10.1016/j.phrs.2020.104749 · DOI
- Ross, 1999, Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633. L759656, and AM630., Br. J. Pharmacol., 126, 665, 10.1038/sj.bjp.0702351 · DOI · Paper page
- Sagar, 2005, Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats., Eur. J. Neurosci., 22, 371, 10.1111/j.1460-9568.2005.04206.x · DOI
- Schatz, 1997, Cannabinoid receptors CB1 and CB2: A characterization of expression and adenylate cyclase modulation within the immune system., Toxicol. Appl. Pharmacol., 142, 278, 10.1006/taap.1996.8034 · DOI · Paper page
- Shapiro, 2021, Allosteric modulation of the cannabinoid 2 receptor confers seizure resistance in mice., Neuropharmacology, 188, 10.1016/j.neuropharm.2021.108448 · DOI
- Soethoudt, 2017, Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity., Nat. Commun., 8, 10.1038/ncomms13958 · DOI · Paper page
- Stansley, 2018, The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia., Curr. Opin. Pharmacol., 38, 31, 10.1016/j.coph.2018.02.003 · DOI
- Stempel, 2016, Cannabinoid type 2 receptors mediate a cell type-specific plasticity in the hippocampus., Neuron, 90, 795, 10.1016/j.neuron.2016.03.034 · DOI · Paper page
- Sun, 2017, Activation of cannabinoid receptor type 2 attenuates surgery-induced cognitive impairment in mice through anti-inflammatory activity., J. Neuroinflamm., 14, 138, 10.1186/s12974-017-0913-7 · DOI
- Thakur, 2009, Latest advances in cannabinoid receptor agonists., Exp. Opin. Ther. Pat., 19, 1647, 10.1517/13543770903436505 · DOI
- Tham, 2019, Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors., Br. J. Pharmacol., 176, 1455, 10.1111/bph.14440 · DOI · Paper page
- Tsou, 1998, Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system., Neuroscience, 83, 393, 10.1016/S0306-4522(97)00436-3 · DOI · Paper page
- Van Sickle, 2005, Identification and functional characterization of brainstem cannabinoid CB2 receptors., Science, 310, 329, 10.1126/science.1115740 · DOI · Paper page
- Volk, 2016, The role of endocannabinoid signaling in cortical inhibitory neuron dysfunction in schizophrenia., Biol. Psychiatry, 79, 595, 10.1016/j.biopsych.2015.06.015 · DOI
- Volk, 2010, Alterations in metabotropic glutamate receptor 1alpha and regulator of G protein signaling 4 in the prefrontal cortex in schizophrenia., Am. J. Psychiatry, 167, 1489, 10.1176/appi.ajp.2010.10030318 · DOI
- Wootten, 2018, Mechanisms of signalling and biased agonism in G protein-coupled receptors., Nat. Rev. Mol. Cell Biol., 19, 638, 10.1038/s41580-018-0049-3 · DOI · Paper page
- Wu, 2013, Activation of the CB2 receptor system reverses amyloid-induced memory deficiency., Neurobiology of Aging, 34, 791, 10.1016/j.neurobiolaging.2012.06.011 · DOI · Paper page
- Xing, 2020, Cryo-EM Structure of the human cannabinoid receptor CB2-G(i) signaling complex., Cell, 180, 645.e, 10.1016/j.cell.2020.01.007 · DOI · Paper page
- Yuan, 2022, In silico prediction and validation of CB2 allosteric binding sites to aid the design of allosteric modulators., Molecules, 27, 10.3390/molecules27020453 · DOI
- Zhang, 2021, Cannabidiol inhibition of murine primary nociceptors: Tight binding to slow inactivated states of Na(v)1.8 channels., J. Neurosci., 41, 6371, 10.1523/jneurosci.3216-20.2021 · DOI
- Zhang, Repeated cocaine administration upregulates CB(2) receptor expression in striatal medium-spiny neurons that express dopamine D(1) receptors in mice., Acta Pharmacol. Sin., 43, 876, 10.1038/s41401-021-00712-6 · DOI
- Zhang, 2015, Species differences in cannabinoid receptor 2 and receptor responses to cocaine self-administration in mice and rats., Neuropsychopharmacology, 40, 1037, 10.1038/npp.2014.297 · DOI
- Zhang, 2017, Expression of functional cannabinoid CB(2) receptor in VTA dopamine neurons in rats., Addic. Biol., 22, 752, 10.1111/adb.12367 · DOI
- Zhang, Cannabinoid CB2 receptors are expressed in glutamate neurons in the red nucleus and functionally modulate motor behavior in mice., Neuropharmacology, 189, 10.1016/j.neuropharm.2021.108538 · DOI
Cited by
Laloli, K. J., Rentsch, P., Stayte, S., & Vissel, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1682979 · Cited by 3
Metadata
- Authors
- Ferranti, A. S., & Foster, D. J.
- Venue
- Frontiers in Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2022-08-11
- Volume
- 16
- ISSN
- 1662-453X
- Cited by
- 15
- References
- 10
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cannabinoid type-2 receptors: An emerging target for regulating schizophrenia-relevant brain circuits. https://app.cochat.ai/papers/10.3389/fnins.2022.925792
- The paper
- Ferranti, A. S., & Foster, D. J. (2022). Cannabinoid type-2 receptors: An emerging target for regulating schizophrenia-relevant brain circuits. Frontiers in Neuroscience. https://doi.org/10.3389/fnins.2022.925792
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.